FIELD: pharmacy.
SUBSTANCE: group of inventions refers to application of the original group of dimeric dipeptides, created based on the structure β-bending of the 4th nerve growth factor loop of a rat and a human, respectively, GC-2 Rat (r) (hexamethylenediamide bis-(N-monosuccinyl-glutamyl-lysine)) and GC-2 Human (h) (hexamethylenediamide bis- (N-monosuccinyl-glycyl-L-lysine)), as antidiabetics.
EFFECT: attenuation of hyperglycaemia during treatment of first and the second type of diabetes.
2 cl, 2 tbl, 6 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
DIMERIC DIPEPTIDE MIMETICS OF NEUROTROFIN-3 | 2022 |
|
RU2800369C1 |
DRUG FOR PREVENTION AND TREATMENT OF DIABETES | 2013 |
|
RU2597848C2 |
AGENT POSSESSING ANTIDIABETIC ACTIVITY | 2017 |
|
RU2693479C2 |
MEDICATION FOR PREVENTION AND CORRECTION OF DIABETES MANIFESTATIONS | 2012 |
|
RU2563234C2 |
PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR PARENTERAL APPLICATION ON BASIS OF HEXAMETHYLENEDIAMINE BIS-(N-MONOSUCCINYL-L-GLUTAMIL-L-LYSINE) IN LYOPHILIZED DOSAGE FORM | 2017 |
|
RU2678203C2 |
DRUG PREPARATION WITH ANTIARRHYTHMIC AND ANTIFIBRILLATORY ACTION | 2010 |
|
RU2477144C2 |
OXOVANADIUM COMPLEXES OF L-MALIC ACID SHOWING HYPOGLYCEMIC ACTIVITY | 1996 |
|
RU2101287C1 |
SUBSTITUTED BISDIPEPTIDE WITH NEUROPROTECTIVE AND ANTIDEPRESSANT EFFECT | 2014 |
|
RU2559880C1 |
PHARMACEUTICAL COMBINATION CONTAINING SGLT2 INHIBITOR | 2008 |
|
RU2489151C2 |
SUBSTANCE WITH ANGIOGENIC ACTIVITY | 2013 |
|
RU2613184C2 |
Authors
Dates
2017-03-15—Published
2013-06-28—Filed